Can Lyft Ever Lift Off or Will It Forever Uber-Underwhelm?
CEO David Risher has been scooping up Lyft shares like surge-priced burritos—and with record rides, rising cash flow, and a $750M buyback plan, the bullish case is stronger than ever. But can LYFT finally fly—or is Uber still driving the narrative?
Can Sweetgreen’s Stock Get Any Less Bitter?
Sweetgreen just served up its first insider buy since IPO—should investors take a bite? The fast-casual salad giant keeps growing but hasn’t turned a profit. We chop into the numbers, spice it up with fun, and toss in all the risks. 🥗📉
Xerox Holdings: This Company Still Exists—To Be or Not To Be... In Your Portfolio?
Xerox might feel like yesterday’s news, but insiders and institutions clearly disagree. With executives loading up on shares and a reinvention strategy underway, this classic name could be more than a relic—it might just be your next contrarian play. 📠💥
Can V.F. Corporation Face North and Land More Than Timber?
Insiders are buying, the CEO’s betting big, and the stitches are finally tightening at V.F. Corp. With a turnaround in motion and brands like Vans and Timberland in the mix, could this stock step back into fashion?
Penn Entertainment: A Double-Down That’s Finally Paying Off?
Penn Entertainment ($PENN) is showing signs of life — insiders are doubling down, revenues are climbing, and digital bets are growing fast. With shares rebounding, is it time to follow the high-rollers or step back from the table? 🎰📈
Middleby: Insiders Are Buying Like Something’s Cooking (and Not Just in the Kitchen…)
Insiders are grabbing shares of Middleby like fresh-baked cookies—$93M worth in May alone. With buybacks, spinoffs, and top-tier equipment across commercial, residential, and food processing, this stock may be more than a kitchen story. Is it time to take a bite?
Viatris: The CEO Just Bought Shares… Should You Pop a Pill or Press "Buy"?
When a CEO personally buys over half a million dollars of stock, it’s time to pay attention. Viatris (VTRS) may be undervalued, with insider confidence, institutional backing, and a promising drug pipeline. But big losses and high debt mean it’s not risk-free. Is now the time to nibble?
Repay Holdings: Time to Reward the Patient Holder?
Insider buying is heating up at Repay Holdings. With over 200 institutions on board and a bargain-bin valuation, this fintech underdog might be getting ready to repay patient investors—with upside.
UnitedHealth Group: What if the Health of Your Portfolio Demands It?
UnitedHealth Group just saw two key insiders drop over $30M into the stock. That’s not a small co-pay—it’s serious belief. The stock is down 50% from its highs, but with strong earnings, defensive sector status, and a new-old CEO at the helm, could this be the comeback your portfolio needs?
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?